Background: This study was designed to explore whether ultrasound of thyroid nodules facilitates the interpretation of the malignant risk of Bethesda III/IV thyroid nodules to inform further therapies.
| INTRODUCTION
Thyroid nodules are clinically common; however, the occurrence of malignancy in thyroid nodules remains relatively low, ranging between 5% and 7%. 1, 2 Ultrasound-guided fine-needle aspiration (US-FNA) is a useful test for the evaluation of thyroid nodules that has been widely applied as the primary diagnostic procedure. 3 FNA results are standardized by the Bethesda System for Reporting Thyroid Cytopathology, which promotes effective communication between clinicians 2, 4 and are divided into six types. Benign nodules are classified as or Bethesda IV (follicular neoplasm or suspicious for follicular neoplasm [FN/SFN]). Thyroid nodules classified as Bethesda II, V, and VI have prescribed management strategies; in contrast, optimal management strategies for uncertain nodules (Bethesda III and IV) remain unclear. The risk of malignancy for Bethesda III is estimated at 5%-15%, 2 and 10%-40% of Bethesda IV nodules are malignant. 3 Due to the large range of malignancy risk, repeated FNA or surgery is recommended, and more than half have a determined diagnostic result. [5] [6] [7] Approximately 15.6%-48.6% of nodules remain AUS/FLUS upon repeat FNA, 5, 6, 8 indicating a need to assess the risk of malignancy in Bethesda system III/IV nodules.
Ultrasound is the preferred method to detect thyroid nodules, and ultrasound factors, such as hypoechogenicity, irregular shape, being taller than wide and microcalcifications, are considered to be features of malignant nodules. Some studies have demonstrated the use of ultrasound to predict the risk of malignancy in Bethesda III and IV thyroid nodules during the initial US-FNA. [9] [10] [11] [12] However, one study demonstrated that the thyroid ultrasound risk stratification system has poor specificity and accuracy for classifying indeterminate lesions. 13 Another study reported that age and gender, but not ultrasound characteristics, influence the decision to perform surgery in AUS/FLUS patients. 14 Since then, no clear guidelines have been established to manage Bethesda III and IV nodules. The purpose of this study was to explore whether ultrasound characteristics of thyroid nodules may facilitate clinicians interpreting the risk of malignancy for Bethesda system III/IV thyroid nodules to inform choices for future therapies. were retrospectively reviewed. US-FNA results were described using the Bethesda System for Reporting Thyroid Cytology (TBSRTC), and patients defined as Bethesda system III/IV were enrolled in our study.
| MATERIALS AND METHODS

| Sonographic evaluation
Patient thyroid nodules were measured using LOGIE9 (GE Healthcare, Wauwatosa, Wisconsin). The transducer was a 5-12 MHz linear transducer. The following ultrasound imaging features of nodules were evaluated: size, shape, being taller than wide, solitary nodules, echogenicity, and calcification. Malignant imaging features included irregular shape, hypoechogenicity, being taller than wide, and microcalcification. Chinese VIP from inception to August 2018 using the keywords: "thyroid," "Bethesda system," "The Bethesda System for Reporting Thyroid Cytology "TBSRTC," "fine-needle aspiration," "FNA," and "FNAC." Inclusion criteria were studies using ultrasound to estimate the malignancy of Bethesda III/IV nodules in the initial US-FNA.
| Search strategy
Reviews and references were also evaluated. Reviews, abstracts, letters, and duplicate data were removed. No language restrictions were applied.
Two authors (Fu Li and Denghua Pan) independently performed the literature search and data screening. When there was controversy, the disagreement was resolved by a third reviewer (Yun He).
| Data extraction
Two investigators (Fu Li and Denghua Pan) independently extracted data from eligible studies. The following characteristics were extracted: first author's name, year of publication, country, and number of patients. To evaluate risk factors associated with thyroid cancer, the following ultrasound parameters were extracted: irregular borders, solitary nodule, hypoechogenicity, microcalcifications, and being taller than wide.
| Statistical analysis
Two independent t-tests and chi-square test were applied to analyze differences between benign and malignant groups using SPSS22.0 (SPSS Inc., Chicago, Illinois). For meta-analysis, the odds ratio (OR) was used to explore associations between risk factors and thyroid nodule malignancy. OR > 1 indicates that risk factors were more likely to correlate with the malignancy of thyroid nodules. For heterogeneity analysis, chi-squared test was used to assess heterogeneity among studies. P < .05 was considered to represent significant heterogeneity, and then a fixed effect model was used. Otherwise, a random effects model was used. Publication bias was measured using funnel plots. Meta-analysis was conducted in STATA12.0 (STATA Corp., College, Texas). P < .05 was considered statistically significant. No significant difference was observed with respect to age between benign and malignant groups (P > .05). In the benign group, average nodule size was 2.51 cm, and in the malignant group, mean nodule size was 1.44 cm, which were significantly different in two groups (P = .019). Additionally, there was a significant difference between benign and malignant groups with respect to patient sex (P = .013) in thyroid nodules. In the malignant groups of thyroid nodules, the parameters of irregular borders, solitary nodules, hypoechogenicity, microcalcifications and being taller than wide were more common (all P < .05). We also compared clinical ultrasound and ultrasonographic characteristics between PTC and benign thyroid nodules ( Table 2 ). The mean age of PTC cases was 41.27 years old, and the average age of the benign group was 46.41 years old, with no significant difference between the two group (P = .119). Average size in the benign group was larger than in the PTC group (P = .023). In addition, there were significant differences in sex, irregular borders, solitary nodules, hypoechogenicity, microcalcifications, and being taller than wide between PTC and benign groups (all P < .05). Figure 1 shows the procedures of this study, which screened 368 studies. After reading full texts of the studies, 16 publications were included in the meta-analysis. 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Table 3 shows the characteristics included studies. All studies had sufficient data to calculate the associations between risk factors and nodules. This meta-analysis observed significant associations between irregular borders, solitary nodules, hypoechogenicity, and microcalcifications and nodules that are being taller than wide or malignant. Combined ORs were 4.08 (95% CI: 2.34-7.14, P < .001; Figure 2A ), 2.18 (95% CI:1.39-3.42, P = .001; Figure 2B ), 2.02 (95% CI:1.35-3.01, P = .001; Figure 2C ), 3.21 (95% CI: 2.26-4.56, P < .001; Figure 2D ), and 4.35 (95% CI: 3.07-6.15, P < .001), respectively, ( Figure 2E ; Table 4 ). Abbreviation: PTC, papillary thyroid carcinoma.
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hypoechogenicity ( Figure 3D , P = .055), and those that are being taller than wide ( Figure 3E , P = .173).
| Discussion
Ultrasound is the preferred method to detect thyroid nodules, and US-FNA is a helpful procedure that provides information for further 30 In addition, ultrasound findings are useful for cytopathologists to manage thyroid nodules with nondiagnostic or unsatisfactory thyroid FNA results. 31 However, the risk of malignancy of Bethesda system III/IV nodules varies widely. Our study explored whether ultrasound characteristics of thyroid nodules facilitate clinicians interpreting the risk for malignancy of Bethesda system III/IV thyroid nodules to inform further therapies.
In our study, thyroid nodules with relatively TI-RADS high scores received FNA, so total ROM of Bethesda system III/IV was 54.2%, which was significantly higher than those from Western practice, 29, [32] [33] [34] demonstrating that TI-RADS reduces the number of unnecessary thyroid nodule FNAs. 35 Second, as we know differentiated thyroid carcinoma (DTC) accounts for more than 90% of all thyroid cancers and DTC is an indolent carcinoma, our practice of triaging patients with Bethesda system III/IV nodules is as follows:
≥TI-RADS 4c with Bethesda system III/IV nodules were referred to surgery; ≤TI-RADS 4a with Bethesda system III/IV nodules were referred for routine observation, with the exception of benign thyroid nodules, which were referred to surgery; for TI-RADS 4b with
Bethesda system III/IV nodules needing further discussion with the patients, possible advice included repeat FNA diagnostic surgery, routine observation, use of other imaging modalities, and so on based on patient preference. 36, 37 F I G U R E 1 Flow diagram of this study. A total of 368 publications and microarray datasets were initially obtained. According to the exclusion criteria, only 16 were subsequently included in this study [Color figure can be viewed at wileyonlinelibrary.com]
In general, ultrasound features suspicious for malignancy include hypoechogenicity, irregular borders, being taller than wide, microcalcifications, and components of the nodules. 38, 39 In our study, differences were observed in the rates of hypoechogenicity, irregular borders, being taller than wide, microcalcifications and components of nodules between benign and malignant groups. Reports indicated that being taller than wide, irregular margins and hypoechogenicity were all associated with malignancy in thyroid nodules, with irregular margins having the highest positive predictive value for malignancy. 38 This observation was also reported by Maia et al 40 in 80 patients surgically treated at a single center. In the present study, we observed irregular borders, hypoechogenicity, microcalcifications, being taller than wide, and components of the nodules all increased the risk for malignancy in thyroid nodules. This finding is in accordance with a study by Kure et al 41, 42 Brito et al 43 demonstrated that being taller than wide had the highest diagnostic OR for judging the malignancy of thyroid nodules compared to other graphic ultrasound features. In our study, a relationship between the dimension of being taller than wide and risk of cancer was observed.
Several studies have confirmed that the majority of malignant thyroid nodules are solid. 44 However, the presence of microcalcifications in partial cystic lesions increase the risk of malignancy. 45 Furthermore, a totally cystic lesion conveys a very low risk of malignancy and can be treated as benign disease. 43 In our study, 93.8% (30/32) of patients had solitary nodules in the two malignancy subgroups, and 48.1% (13/27) had solitary nodules in the two benign subgroups. We found that solitary nodules increased the risk for malignancy in patients.
The risk and incidence of malignancy in Bethesda system III/IV nodules varies widely. When nodules are diagnosed as Bethesda system III/IV, it is a challenge for clinicians to decide whether to recommend surgery, repeated US-FNA or follow-up. One study reported that repeated US-FNA can be performed 6 months or more after initial AUS/FLUS. 46 Rossi Met et al 47 Figure 4A shows that a solid thyroid nodule was located in the left lobe of the thyroid. The nodule was a hypoechoic nodule with irregular border and microcalcifications (TI-RADS 4c). FNA was conducted, and results revealed cytological atypia: focal nuclear changes with extensive but mild nuclear changes ( Figure 4B , Figure 4C ). Therefore, we diagnosed this thyroid nodule as AUS/FLUS.
Finally, the patient decided to undergo surgery to resect this nodule, and the histopathology was PTC ( Figure 4D ). Figure 5 was a case of an FN/SFN thyroid nodule. Figure 5A shows a solid thyroid nodule located in the right lobe of the thyroid. The nodule was hypoechoic with irregular border and macrocalcifications (TI-RADS 4b).
FNA results showed mild nuclear changes (increased nuclear size, nuclear contour irregularity) without true papillae and intranuclear pseudoinclusions ( Figure 5B,C) . We diagnosed this thyroid nodule as FN/SFN and recommended surgery for this patient. Histopathology of this thyroid nodule was FTC ( Figure 5D ). In this study, we unveiled significant associations between solitary nodules, hypoechogenicity, irregular borders, being taller than wide, microcalcifications, and malignant nodules. Figure 4A shows a solid thyroid nodule located in the left lobe of the thyroid. The nodule was hypoechoic with irregular border and microcalcifications (TI-RADS 4c). Figure 4B ,C show cytological atypia: focal nuclear changes and extensive but mild nuclear changes (×400). Hence, we diagnosed this thyroid nodule as atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS). Figure 4D shows Figure 5A shows a solid thyroid nodule located in the right lobe of the thyroid. The nodule was hypoechoic with irregular border and macrocalcifications (TI-RADS 4b). Figure 5B ,C show mild nuclear changes (increased nuclear size, nuclear contour irregularity) without true papillae and intranuclear pseudoinclusions (×400). Hence, we diagnosed this thyroid nodule as follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN). Figure 5D shows the histopathology was FTC for this thyroid nodule (×40) [Color figure can be viewed at wileyonlinelibrary.com]
